Kyverna Therapeutics, INC. (KYTX) — 10-Q Filings

10-Q Filings (6)

• Kyverna's Losses Widen Amid Soaring R&D Costs — Nov 12, 2025 Risk: high
  Kyverna Therapeutics, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $123.5 million, up from $89.988 mi
• Kyverna's Q2 Loss Widens on Soaring R&D for Autoimmune Therapies — Aug 12, 2025 Risk: high
  Kyverna Therapeutics, Inc. (KYTX) reported a significant increase in net loss for the six months ended June 30, 2025, reaching $86.7 million, up from $55.5 mill
• Kyverna Therapeutics Files 10-Q Post-IPO — May 13, 2025 Risk: medium
  Kyverna Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported research and development expenses for the first quarter of
• Kyverna Therapeutics Q3 2024 Update — Nov 13, 2024 Risk: medium
  Kyverna Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported research and development expenses for the third quarter
• Kyverna Therapeutics Files Q2 2024 10-Q — Aug 12, 2024 Risk: medium
  Kyverna Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial status, including details on its cash, investm
• Kyverna Therapeutics Files 10-Q for Period Ending March 31, 2024 — May 14, 2024 Risk: medium
  Kyverna Therapeutics, Inc. (KYTX) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Kyverna Therapeutics, Inc. filed a 10-Q for the period ending Ma

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX